Plus Therapeutics, Inc. (NASDAQ:PSTV) Receives $7.25 Average Target Price from Brokerages

Plus Therapeutics, Inc. (NASDAQ:PSTV) has earned a consensus recommendation of “Moderate Buy” from the seven research firms that are currently covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating, four have assigned a buy rating and one has issued a strong buy rating on the company. The average twelve-month price objective among brokers that have covered the stock in the last year is $7.25.

Several research analysts have recently issued reports on the company. Weiss Ratings restated a “sell (e+)” rating on shares of Plus Therapeutics in a research report on Wednesday, October 8th. D. Boral Capital reissued a “buy” rating and set a $5.00 target price on shares of Plus Therapeutics in a research report on Thursday, January 8th. HC Wainwright restated a “buy” rating and issued a $2.00 target price on shares of Plus Therapeutics in a research note on Wednesday, November 26th. Zacks Research lowered Plus Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, November 11th. Finally, Ascendiant Capital Markets dropped their price target on shares of Plus Therapeutics from $21.00 to $19.00 and set a “buy” rating on the stock in a report on Friday, November 21st.

Hedge Funds Weigh In On Plus Therapeutics

Institutional investors have recently added to or reduced their stakes in the business. Altium Capital Management LLC acquired a new position in Plus Therapeutics in the third quarter worth approximately $628,000. Scientech Research LLC acquired a new stake in shares of Plus Therapeutics during the 3rd quarter worth about $100,000. Jane Street Group LLC bought a new position in Plus Therapeutics in the second quarter valued at about $41,000. Finally, Susquehanna International Group LLP purchased a new stake in shares of Plus Therapeutics in the third quarter valued at about $46,000. 3.28% of the stock is currently owned by institutional investors and hedge funds.

Plus Therapeutics Price Performance

Shares of NASDAQ PSTV opened at $0.29 on Thursday. The firm has a market capitalization of $39.97 million, a PE ratio of -0.15 and a beta of 0.85. Plus Therapeutics has a 1-year low of $0.16 and a 1-year high of $2.31. The business’s fifty day moving average price is $0.56 and its two-hundred day moving average price is $0.54.

Plus Therapeutics (NASDAQ:PSTV) last issued its quarterly earnings data on Thursday, October 30th. The company reported ($0.04) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.02). The company had revenue of $1.40 million for the quarter, compared to analyst estimates of $1.50 million. Equities research analysts expect that Plus Therapeutics will post -2.3 earnings per share for the current fiscal year.

Plus Therapeutics Company Profile

Plus Therapeutics is a clinical‐stage biopharmaceutical company specializing in the development of targeted radiotherapeutics for oncology. Its platform technologies leverage nanoliposomes and microspheres to deliver therapeutic radioisotopes directly to tumor sites. The company’s lead candidate, 90Y-HP-DO3A, is in Phase 2 development for recurrent high-grade gliomas, while its rhenium-based nanoliposome program is under investigation for diffuse intrinsic pontine glioma and brain metastases.

The pipeline also includes investigational treatments for bone metastases, malignant pleural effusions and other hard-to-treat solid tumors.